Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 802

Prof Alessandro Rambaldi - University of Milan, Milan, Italy

Prof Alessandro Rambaldi speaks to ecancer at ASH 2018 about the phase 2 study looking into blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL.

He explains that although the frontline treatment for NHL is very effective, the outcome for those who relapse is poor, hence the need for a second salvage therapy.

Prof Rambaldi reports that treatment with blinatumomab achieved a 37% overall response and that these patients could go on to receive an autologous stem cell transplant.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation